Sugi Predict

Sugi Predict / Targets / FOLH1

FOLH1

Glutamate carboxypeptidase 2 · Q04609 · FOLH1 on Sugi Atlas →

145,257 patent compounds predicted against FOLH1, 76,199 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL108166 SCHEMBL108166 0.76 15/20
SCHEMBL28640 SCHEMBL28640 1.00 14/20
SCHEMBL107884 SCHEMBL107884 0.65 14/20
SCHEMBL22058 SCHEMBL22058 0.61 13/20
SCHEMBL40047 SCHEMBL40047 1.00 9/20
SCHEMBL29217 SCHEMBL29217 0.68 9/20
SCHEMBL65743 SCHEMBL65743 0.50 9/20
SCHEMBL65744 SCHEMBL65744 0.50 9/20
SCHEMBL71843 SCHEMBL71843 0.43 9/20
SCHEMBL148582 SCHEMBL148582 0.75 8/20
SCHEMBL148583 SCHEMBL148583 0.75 8/20
Acetylglutamic Acid Acetylglutamic Acid (SCHEMBL82128) 0.69 8/20
SCHEMBL73336 SCHEMBL73336 0.63 8/20
SCHEMBL136060 SCHEMBL136060 0.59 8/20
SCHEMBL136061 SCHEMBL136061 0.59 8/20
SCHEMBL156084 SCHEMBL156084 0.56 8/20
SCHEMBL72024 SCHEMBL72024 0.52 8/20
SCHEMBL141783 SCHEMBL141783 0.61 7/20
SCHEMBL147131 SCHEMBL147131 0.59 7/20
SCHEMBL148076 SCHEMBL148076 0.57 7/20

Clinical trials — most relevant to FOLH1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients PHASE2/PHASE3UNKNOWN
68Ga-P16-093 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients PHASE2/PHASE3UNKNOWN
PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer PHASE3RECRUITING
68Ga-P16-093 PET/CT Imaging in Glioma Patients PHASE1/PHASE2UNKNOWN
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer PHASE2ACTIVE_NOT_RECRUITING
68Ga-P16-093 PET/CT Imaging in the Salivary Gland PHASE1/PHASE2UNKNOWN
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer PHASE2COMPLETED
Study of 18F-Thretide PET/CT in Patients With Prostate Cancer PHASE1/PHASE2COMPLETED
Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours: PHASE2ACTIVE_NOT_RECRUITING
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study PHASE2RECRUITING
Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET PHASE1COMPLETED
68Ga-AAZTA-NI-093 PET/CT: First-in-human Study EARLY_PHASE1RECRUITING
68Ga-AAZTA-093 PET/CT: First-in-human Study EARLY_PHASE1UNKNOWN
18F-DCFBC PET/CT in Prostate Cancer EARLY_PHASE1COMPLETED
PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer EARLY_PHASE1COMPLETED
68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study nanRECRUITING
68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients nanCOMPLETED
68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients nanRECRUITING
Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma nanUNKNOWN
A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer nanRECRUITING
Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient nanRECRUITING
Superior Cervical Ganglion in Parkinson's Disease nanRECRUITING
18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC) nanCOMPLETED
PSMA Expression and PSMA PET Imaging in Soft Tissue Sarcomas and Urothelial Cell Carcinomas nanCOMPLETED
Multi-modality Prostate Cancer Image Guided Interventions nanCOMPLETED
Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007 nanCOMPLETED
The Application Value of 18F-prostate-specific Membrane Antigen PET/CT in Prostate Cancer nanUNKNOWN
The Application Value of Prostate Specific Membrane Antigen PET/CT in Biopsy Free of PSA Grey Area Prostate Cancer nanCOMPLETED
Expanded Access Protocol of 68Ga-PSMA-11 for PET Imaging nanAPPROVED_FOR_MARKETING
PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a FOLH1 binder may also engage these)

ProteinNameSimilarity
O77564 — 0.999 O77564 →
NAALAD2 N-acetylated-alpha-linked acidic dipeptidase 2 0.997 landscape →
Q9CZR2 — 0.995 Q9CZR2 →
P70627 — 0.994 P70627 →
Q9HBA9 — 0.991 Q9HBA9 →
O35409 — 0.991 O35409 →
Q6IRK9 — 0.973 Q6IRK9 →
Q5RDN7 — 0.971 Q5RDN7 →
Q17QK3 — 0.970 Q17QK3 →
Q9Y646 — 0.967 Q9Y646 →
Q9WVJ3 — 0.965 Q9WVJ3 →
P21588 — 0.956 P21588 →
NT5E 5'-nucleotidase 0.955 landscape →
B6EWW8 — 0.955 B6EWW8 →
TPP2 Tripeptidyl-peptidase 2 0.955 landscape →
A1A4K5 — 0.955 A1A4K5 →
Q6GQ29 — 0.954 Q6GQ29 →
Q9JHP7 — 0.954 Q9JHP7 →
P07687 — 0.953 P07687 →
GLS2 Glutaminase liver isoform, mitochondrial 0.953 landscape →
Q61503 — 0.953 Q61503 →
EPHX1 Epoxide hydrolase 1 0.953 landscape →
Q9QX15 — 0.953 Q9QX15 →
Q9R1E6 — 0.953 Q9R1E6 →
ENPP2 Autotaxin 0.952 landscape →
Q64560 — 0.952 Q64560 →
P04068 — 0.951 P04068 →
Q6GQI7 — 0.951 Q6GQI7 →
P08430 — 0.951 P08430 →
P58242 — 0.951 P58242 →